ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 37 filers reported holding ALIGOS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,733,325 | -23.1% | 2,320,381 | 0.0% | 0.92% | -65.5% |
| Q2 2023 | $2,253,090 | +11.1% | 2,320,381 | 0.0% | 2.67% | -36.8% |
| Q1 2023 | $2,028,013 | -8.3% | 2,320,381 | 0.0% | 4.23% | -7.6% |
| Q4 2022 | $2,211,091 | -13.4% | 2,320,381 | 0.0% | 4.58% | +5.1% |
| Q3 2022 | $2,552,000 | -9.1% | 2,320,381 | 0.0% | 4.35% | +1.1% |
| Q2 2022 | $2,808,000 | -43.7% | 2,320,381 | 0.0% | 4.30% | -13.6% |
| Q1 2022 | $4,989,000 | -81.9% | 2,320,381 | 0.0% | 4.98% | -66.2% |
| Q4 2021 | $27,543,000 | -23.5% | 2,320,381 | 0.0% | 14.73% | -1.1% |
| Q3 2021 | $35,989,000 | -23.9% | 2,320,381 | 0.0% | 14.90% | -4.9% |
| Q2 2021 | $47,301,000 | -36.8% | 2,320,381 | -29.5% | 15.67% | +7.4% |
| Q1 2021 | $74,868,000 | -17.8% | 3,292,339 | 0.0% | 14.59% | +54.3% |
| Q4 2020 | $91,033,000 | – | 3,292,339 | – | 9.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,320,381 | $47,301,000 | 15.67% |
| Pivotal bioVenture Partners Investment Advisor LLC | 876,548 | $17,873,000 | 7.04% |
| Vivo Capital, LLC | 3,547,030 | $72,306,000 | 3.13% |
| Novo Holdings A/S | 2,614,563 | $53,311,000 | 2.36% |
| ACUTA CAPITAL PARTNERS, LLC | 214,254 | $4,368,000 | 1.75% |
| Boxer Capital, LLC | 1,526,048 | $31,108,000 | 1.10% |
| VR Adviser, LLC | 408,377 | $8,325,000 | 1.01% |
| Cormorant Asset Management, LP | 905,467 | $18,458,000 | 0.63% |
| HHLR ADVISORS, LTD. | 2,165,064 | $44,135,000 | 0.45% |
| Logos Global Management LP | 212,785 | $4,339,000 | 0.36% |